This company listing is no longer active
3N9A Stock Overview
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 3N9A from our risk checks.
Amryt Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.90 |
| 52 Week High | US$13.20 |
| 52 Week Low | US$6.20 |
| Beta | 0.75 |
| 1 Month Change | -0.77% |
| 3 Month Change | 0% |
| 1 Year Change | 89.71% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 38.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3N9A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 3.2% | 1.7% |
| 1Y | 89.7% | -28.2% | 2.3% |
Return vs Industry: 3N9A exceeded the German Pharmaceuticals industry which returned -10.8% over the past year.
Return vs Market: 3N9A exceeded the German Market which returned -6.9% over the past year.
Price Volatility
| 3N9A volatility | |
|---|---|
| 3N9A Average Weekly Movement | 1.5% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3N9A's share price has been volatile over the past 3 months.
Volatility Over Time: 3N9A's weekly volatility has decreased from 15% to 1% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 289 | Joe Wiley | www.amrytpharma.com |
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB.
Amryt Pharma plc Fundamentals Summary
| 3N9A fundamental statistics | |
|---|---|
| Market cap | €851.40m |
| Earnings (TTM) | -€715.03k |
| Revenue (TTM) | €220.50m |
3.9x
P/S Ratio-1,191x
P/E RatioIs 3N9A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3N9A income statement (TTM) | |
|---|---|
| Revenue | US$243.62m |
| Cost of Revenue | US$111.31m |
| Gross Profit | US$132.32m |
| Other Expenses | US$133.11m |
| Earnings | -US$790.00k |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 54.31% |
| Net Profit Margin | -0.32% |
| Debt/Equity Ratio | 64.3% |
How did 3N9A perform over the long term?
See historical performance and comparison